• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ELISPOT 检测反应定义标准的再探讨。

Response definition criteria for ELISPOT assays revisited.

机构信息

Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

出版信息

Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15.

DOI:10.1007/s00262-010-0875-4
PMID:20549207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2909425/
Abstract

No consensus has been reached on how to determine if an immune response has been detected based on raw data from an ELISPOT assay. The goal of this paper is to enable investigators to understand and readily implement currently available methods for response determination. We describe empirical and statistical approaches, identifying the strengths and limitations of each approach to allow readers to rationally select and apply a scientifically sound method appropriate to their specific laboratory setting. Five representative approaches were applied to data sets from the CIMT Immunoguiding Program and the response detection and false positive rates were compared. Simulation studies were also performed to compare empirical and statistical approaches. Based on these, we recommend the use of a non-parametric statistical test. Further, we recommend that six medium control wells or four wells each for both medium control and experimental conditions be performed to increase the sensitivity in detecting a response, that replicates with large variation in spot counts be filtered out, and that positive responses arising from experimental spot counts below the estimated limit of detection be interpreted with caution. Moreover, a web-based user interface was developed to allow easy access to the recommended statistical methods. This interface allows the user to upload data from an ELISPOT assay and obtain an output file of the binary responses.

摘要

尚未就如何根据 ELISPOT 检测的原始数据确定是否检测到免疫反应达成共识。本文的目的是使研究人员能够理解和轻松实施当前可用的反应确定方法。我们描述了经验和统计方法,确定了每种方法的优缺点,以便读者能够合理选择并应用适合其特定实验室环境的科学合理的方法。将五种代表性方法应用于 CIMT Immunoguiding 计划的数据集中,并比较了反应检测和假阳性率。还进行了模拟研究来比较经验和统计方法。在此基础上,我们建议使用非参数统计检验。此外,我们建议进行六个中等对照孔或每个中等对照和实验条件各四个孔,以提高检测反应的灵敏度,滤除斑点计数变化较大的重复孔,并谨慎解释来自实验斑点计数低于估计检测限的阳性反应。此外,还开发了一个基于网络的用户界面,以方便访问推荐的统计方法。该界面允许用户从 ELISPOT 检测中上传数据,并获得二进制响应的输出文件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1772/11030815/84ed298a1feb/262_2010_875_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1772/11030815/4a9d53eb6358/262_2010_875_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1772/11030815/7248bb7424f6/262_2010_875_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1772/11030815/84ed298a1feb/262_2010_875_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1772/11030815/4a9d53eb6358/262_2010_875_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1772/11030815/7248bb7424f6/262_2010_875_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1772/11030815/84ed298a1feb/262_2010_875_Fig3_HTML.jpg

相似文献

1
Response definition criteria for ELISPOT assays revisited.ELISPOT 检测反应定义标准的再探讨。
Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15.
2
Statistical analysis of ELISPOT assays.酶联免疫斑点试验(ELISPOT)的统计分析。
Methods Mol Biol. 2012;792:173-83. doi: 10.1007/978-1-61779-325-7_14.
3
Normal Distribution of CD8+ T-Cell-Derived ELISPOT Counts within Replicates Justifies the Reliance on Parametric Statistics for Identifying Positive Responses.CD8+ T 细胞衍生 ELISPOT 计数在重复实验中的正态分布证明了依赖参数统计来识别阳性反应的合理性。
Cells. 2015 Mar 2;4(1):96-111. doi: 10.3390/cells4010096.
4
Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.验证用于检测黑色素瘤患者对gp100和MelanA/MART-1免疫反应的HLA-A2四聚体流式细胞术方法、IFNγ实时逆转录聚合酶链反应以及IFNγ酶联免疫斑点法。
J Transl Med. 2008 Oct 22;6:61. doi: 10.1186/1479-5876-6-61.
5
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.血清不是体外 IFN-γ ELISPOT 所必需的:来自欧洲 CIMT 免疫指导计划的不同方案的协作研究。
Cancer Immunol Immunother. 2010 Apr;59(4):619-27. doi: 10.1007/s00262-009-0814-4. Epub 2010 Jan 6.
6
Evaluating ELISPOT summary measures with criteria for obtaining reliable estimates.使用获取可靠估计值的标准评估ELISPOT汇总指标。
J Immunol Methods. 2005 Feb;297(1-2):97-108. doi: 10.1016/j.jim.2004.12.006.
7
Evaluation of Elispot assays: influence of method and operator on variability of results.酶联免疫斑点试验(Elispot)分析评估:方法和操作人员对结果变异性的影响。
J Immunol Methods. 2004 Aug;291(1-2):175-83. doi: 10.1016/j.jim.2004.06.008.
8
Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies.在能力验证和桥接研究背景下,干扰素-γ酶联免疫斑点试验的变异性
J Immunol Methods. 2016 Jun;433:69-76. doi: 10.1016/j.jim.2016.03.004. Epub 2016 Mar 25.
9
A novel ELISpot method for adherent cells.一种用于贴壁细胞的新型酶联免疫斑点法。
J Immunol Methods. 2004 Aug;291(1-2):63-70. doi: 10.1016/j.jim.2004.04.023.
10
Comparison of an in-house and a commercial RD1-based ELISPOT-IFN-gamma assay for the diagnosis of Mycobacterium tuberculosis infection.用于诊断结核分枝杆菌感染的内部研发的和基于RD1的商业酶联免疫斑点法检测γ干扰素的比较。
Clin Med Res. 2006 Dec;4(4):266-72. doi: 10.3121/cmr.4.4.266.

引用本文的文献

1
Cellular Immune Response in Horses After West Nile Neuroinvasive Disease.西尼罗河神经侵袭性疾病后马的细胞免疫反应
Animals (Basel). 2025 Aug 11;15(16):2352. doi: 10.3390/ani15162352.
2
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.UCPVax是一种CD4辅助肽疫苗,可诱导多功能Th1细胞、抗体反应和表位扩展,以增强抗肿瘤免疫力。
Cell Rep Med. 2025 Jul 15;6(7):102196. doi: 10.1016/j.xcrm.2025.102196. Epub 2025 Jun 20.
3
Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4 T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial.

本文引用的文献

1
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.血清不是体外 IFN-γ ELISPOT 所必需的:来自欧洲 CIMT 免疫指导计划的不同方案的协作研究。
Cancer Immunol Immunother. 2010 Apr;59(4):619-27. doi: 10.1007/s00262-009-0814-4. Epub 2010 Jan 6.
2
Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.鉴定影响基于 ELISpot 的细胞对结核分枝杆菌抗原反应监测的主要因素。
PLoS One. 2009 Nov 24;4(11):e7972. doi: 10.1371/journal.pone.0007972.
3
"MIATA"-minimal information about T cell assays.
前列腺癌患者接种抗RhoC疫苗可诱导强大且持久的具有细胞溶解潜力的CD4 T细胞反应,但无临床疗效:一项随机II期试验。
Vaccines (Basel). 2025 Apr 5;13(4):390. doi: 10.3390/vaccines13040390.
4
HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.乳腺癌中ESR1和PIK3CA公共新抗原中的HLA II类限制性T细胞表位
BMC Cancer. 2025 Apr 4;25(1):610. doi: 10.1186/s12885-025-13992-6.
5
Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.基于人类与共生抗原之间的模拟策略开发新型癌症免疫治疗方法。
J Immunother Cancer. 2025 Feb 20;13(2):e010192. doi: 10.1136/jitc-2024-010192.
6
Deciphering cellular complexity: advances and future directions in single-cell protein analysis.解析细胞复杂性:单细胞蛋白质分析的进展与未来方向
Front Bioeng Biotechnol. 2025 Jan 14;12:1507460. doi: 10.3389/fbioe.2024.1507460. eCollection 2024.
7
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.曲氟尿苷/替匹嘧啶±贝伐单抗联合XB2001(抗IL-1α抗体)的安全性和有效性:一项单中心1期试验
Signal Transduct Target Ther. 2025 Jan 17;10(1):22. doi: 10.1038/s41392-024-02116-4.
8
The T cell receptor β chain repertoire of tumor infiltrating lymphocytes improves neoantigen prediction and prioritization.肿瘤浸润淋巴细胞的 T 细胞受体 β 链谱可改善新抗原的预测和优先级排序。
Elife. 2024 Oct 28;13:RP94658. doi: 10.7554/eLife.94658.
9
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, co-mutated metastatic NSCLC.病例报告:PD-L1 阴性、TMB 低、共突变转移性 NSCLC 假性进展的免疫反应特征。
Front Immunol. 2024 Aug 7;15:1437961. doi: 10.3389/fimmu.2024.1437961. eCollection 2024.
10
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.一种新抗原共享疫苗联合免疫检查点阻断治疗晚期转移性实体瘤的 1 期临床试验中期结果。
Nat Med. 2024 Apr;30(4):1013-1022. doi: 10.1038/s41591-024-02851-9. Epub 2024 Mar 27.
“MIATA”——关于T细胞检测的最低限度信息
Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.
4
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".生物标志物发现的系统方法;“国际输血协会-美国食品药品监督管理局免疫治疗生物标志物特别工作组”前言
J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81.
5
Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines.是否适用?案例研究:用于检测针对抗肿瘤DNA融合疫苗的细胞和体液反应的免疫终点分析的验证
Cancer Immunol Immunother. 2009 May;58(5):789-800. doi: 10.1007/s00262-008-0633-z. Epub 2008 Dec 10.
6
Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.新型结核病疫苗试验的免疫学结果:世界卫生组织专家组建议
PLoS Med. 2008 Jul 1;5(7):e145. doi: 10.1371/journal.pmed.0050145.
7
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.使用巨细胞病毒(CMV)肽对干扰素γ(IFNγ)酶联免疫斑点试验、细胞因子流式细胞术和四聚体分析进行验证的精密度和线性目标。
BMC Immunol. 2008 Mar 17;9:9. doi: 10.1186/1471-2172-9-9.
8
Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding.癌症治疗性疫苗:从免疫监测到免疫引导
Expert Rev Vaccines. 2008 Feb;7(1):1-5. doi: 10.1586/14760584.7.1.1.
9
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.CIMT监测小组:一种通过结构和功能检测来协调抗原特异性CD8 + T淋巴细胞计数的两步法。
Cancer Immunol Immunother. 2008 Mar;57(3):289-302. doi: 10.1007/s00262-007-0378-0. Epub 2007 Aug 25.
10
Toward the harmonization of immune monitoring in clinical trials: quo vadis?迈向临床试验中免疫监测的协调统一:路在何方?
Cancer Immunol Immunother. 2008 Mar;57(3):285-8. doi: 10.1007/s00262-007-0379-z. Epub 2007 Aug 25.